Taysha Gene Therapies reported earnings of -$ 0.10 per TSHA share on Nov 12, 2026, falling short of analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 0.13 |
| Earnings Per Share (Surprise) | -$ 0.10 (+$ 0.02857) |
| Last Year's EPS | -$ 0.09 |
| EPS YoY Change |
Out of the last 28 earnings reporting periods, Taysha Gene Therapies beat analysts’ expectations 10 times and fell short of expectations 13 time(s). Taysha Gene Therapies reported earnings per share of -$ 0.10 in the last report surpassing an estimated EPS of -$ 0.13 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.13 | -$ 0.10 | -$ 0.09 | |
| Aug 11, 2026 | -$ 0.11 | -$ 0.13 | -$ 0.09 | |
| May 6, 2026 | -$ 0.10 | -$ 0.12 | -$ 0.08 | |
| Mar 19, 2026 | -$ 0.11 | -$ 0.08 | -$ 0.07 | |
| Nov 4, 2025 | -$ 0.09 | -$ 0.09 | -$ 0.09 | |
| Aug 12, 2025 | -$ 0.07 | -$ 0.09 | -$ 0.09 | |
| May 15, 2025 | -$ 0.08 | -$ 0.08 | -$ 0.10 | |
| Feb 26, 2025 | -$ 0.08 | -$ 0.07 | $ 0.35 | |
| Nov 13, 2024 | -$ 0.08 | -$ 0.09 | -$ 0.13 | |
| Aug 12, 2024 | -$ 0.10 | -$ 0.09 | -$ 0.38 | |
| May 14, 2024 | -$ 0.11 | -$ 0.10 | -$ 0.28 | |
| Mar 19, 2024 | -$ 0.09 | $ 0.35 | -$ 0.99 | |
| Nov 14, 2023 | -$ 0.17 | -$ 0.13 | -$ 0.64 | |
| Aug 14, 2023 | -$ 0.31 | -$ 0.38 | -$ 0.84 | |
| May 11, 2023 | -$ 0.35 | -$ 0.28 | -$ 1.31 | |
| Mar 28, 2023 | -$ 0.41 | -$ 0.99 | -$ 1.32 | |
| Nov 8, 2022 | -$ 0.89 | -$ 0.64 | -$ 1.35 | |
| Aug 11, 2022 | -$ 1.05 | -$ 0.84 | -$ 1.09 | |
| May 16, 2022 | -$ 1.04 | -$ 1.31 | -$ 0.87 | |
| Mar 31, 2022 | -$ 1.21 | -$ 1.32 | -$ 1.04 |
Taysha Gene Therapies’s stock was trading at $ 4.28 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, TSHA’s price decreased to $ 4.10 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.10 | $ 4.28 | $ 4.10 | |
| Aug 11, 2026 | -$ 0.13 | $ 6.37 | $ 6.41 | |
| May 6, 2026 | -$ 0.12 | $ 6.94 | $ 6.67 | |
| Mar 19, 2026 | -$ 0.08 | $ 4.45 | $ 4.40 | |
| Nov 4, 2025 | -$ 0.09 | $ 4.46 | $ 4.03 | |
| Aug 12, 2025 | -$ 0.09 | $ 2.76 | $ 3.03 | |
| May 15, 2025 | -$ 0.08 | $ 2.37 | $ 2.70 | |
| Feb 26, 2025 | -$ 0.07 | $ 1.70 | $ 1.59 | |
| Nov 13, 2024 | -$ 0.09 | $ 2.39 | $ 2.27 | |
| Aug 12, 2024 | -$ 0.09 | $ 2.09 | $ 2.28 | |
| May 14, 2024 | -$ 0.10 | $ 2.40 | $ 3.11 | |
| Mar 19, 2024 | $ 0.35 | $ 2.13 | $ 2.96 | |
| Nov 14, 2023 | -$ 0.13 | $ 1.33 | $ 1.68 | |
| Aug 14, 2023 | -$ 0.38 | $ 0.739 | $ 2.18 | |
| May 11, 2023 | -$ 0.28 | $ 0.75 | $ 0.6714 | |
| Mar 28, 2023 | -$ 0.99 | $ 0.695 | $ 0.6501 | |
| Nov 8, 2022 | -$ 0.64 | $ 2.00 | $ 1.89 | |
| Aug 11, 2022 | -$ 0.84 | $ 4.88 | $ 4.10 | |
| May 16, 2022 | -$ 1.31 | $ 3.44 | $ 3.30 | |
| Mar 31, 2022 | -$ 1.32 | $ 6.15 | $ 6.34 |
Taysha Gene Therapies released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Taysha Gene Therapies beat analysts’ expectations during the last earnings period by
